{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:35:53Z","timestamp":1791012953623,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jtct.2025.01.886","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T11:16:12Z","timestamp":1737803772000},"page":"236.e1-236.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Cognitive Outcomes in Adult Patients Receiving Chimeric Antigen Receptor T-Cell Therapies"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0297-5920","authenticated-orcid":false,"given":"Anna","family":"Barata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Connor","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0163-2061","authenticated-orcid":false,"given":"Tejaswini M.","family":"Dhawale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-6961","authenticated-orcid":false,"given":"Richard A.","family":"Newcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9136-9644","authenticated-orcid":false,"given":"Hermion L.","family":"Amonoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell W.","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6086-5626","authenticated-orcid":false,"given":"Dagny","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3306-2622","authenticated-orcid":false,"given":"Kyle","family":"Karpinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8012-5991","authenticated-orcid":false,"given":"Giuliana V.","family":"Zarrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa M.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-0136","authenticated-orcid":false,"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej","family":"El-Jawahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8619-9564","authenticated-orcid":false,"given":"Michael W.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2025.01.886_bib0001","article-title":"Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies","author":"Abbasi","year":"2022","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.886_bib0002","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtct.2025.01.886_bib0003","article-title":"Bright future or blind alley? CAR-T cell therapy for solid tumors","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.886_bib0004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.36401\/JIPO-22-7","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors: the past and the future","volume":"6","author":"Srour","year":"2023","journal-title":"J Immunother Precis Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.886_bib0005","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10297","key":"10.1016\/j.jtct.2025.01.886_bib0006","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.886_bib0007","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jtct.2025.01.886_bib0008","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2025.01.886_bib0009","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1093\/neuonc\/noad118","article-title":"Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol"},{"issue":"26","key":"10.1016\/j.jtct.2025.01.886_bib0010","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.886_bib0011","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13058-018-1062-3","article-title":"Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study","volume":"20","author":"van der Willik","year":"2018","journal-title":"Breast Cancer Res"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.886_bib0012","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/bmt.2008.217","article-title":"Neuropsychological outcome in very young hematopoietic SCT recipients in relation to pretransplant conditioning","volume":"42","author":"Smedler","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.886_bib0013","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.bbi.2019.04.008","article-title":"Worsening cognitive performance is associated with increases in systemic inflammation following hematopoietic cell transplantation","volume":"80","author":"Hoogland","year":"2019","journal-title":"Brain Behav Immun"},{"issue":"13","key":"10.1016\/j.jtct.2025.01.886_bib0014","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1002\/cncr.26645","article-title":"Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation","volume":"118","author":"Jim","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.886_bib0015","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1017\/S1478951518000664","article-title":"A mixed methods analysis of perceived cognitive impairment in hematopoietic stem cell transplant survivors","volume":"17","author":"Wu","year":"2019","journal-title":"Palliat Support Care"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.886_bib0016","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.bbmt.2010.01.003","article-title":"Impact of delirium on distress, health-related quality of life, and cognition 6 months and 1 year after hematopoietic cell transplant","volume":"16","author":"Basinski","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.886_bib0017","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41409-017-0055-7","article-title":"Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and quality of life working committee of the CIBMTR and complications and quality of life working party of the EBMT","volume":"53","author":"Buchbinder","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"10.1016\/j.jtct.2025.01.886_bib0018","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.18.02363","article-title":"Why are objective and perceived cognitive function weakly correlated in patients with cancer?","volume":"37","author":"Costa","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.886_bib0019","doi-asserted-by":"crossref","first-page":"401.e1","DOI":"10.1016\/j.jtct.2022.05.015","article-title":"Change in patients' perceived cognition following chimeric antigen receptor T-cell therapy for lymphoma","volume":"28","author":"Barata","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.886_bib0020","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","article-title":"Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"6","author":"Delforge","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.886_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42466-021-00166-5","article-title":"Neurological management and work-up of neurotoxicity associated with CAR T cell therapy","volume":"4","author":"M\u00f6hn","year":"2022","journal-title":"Neurol Res Pract"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.886_bib0022","doi-asserted-by":"crossref","first-page":"254.e1","DOI":"10.1016\/j.jtct.2023.01.004","article-title":"Multi-stakeholder qualitative interviews to inform measurement of patient reported outcomes after CAR-T","volume":"29","author":"Akinola","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.886_bib0023","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jtct.2022.05.004","article-title":"Longitudinal patient reported outcomes with CAR-T cell therapy versus autologous and allogeneic stem cell transplant","volume":"28","author":"Sidana","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2025.01.886_bib0024","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/neuonc\/noab077","article-title":"Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study","volume":"23","author":"Maillet","year":"2021","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2025.01.886_bib0025","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1212\/WNL.0000000000201083","article-title":"Long-term neurologic safety in patients with B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy","volume":"99","author":"Ursu","year":"2022","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.886_bib0026","doi-asserted-by":"crossref","first-page":"305.e1","DOI":"10.1016\/j.jtct.2022.03.023","article-title":"Change in neurocognitive performance among patients with non-Hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy","volume":"28","author":"Hoogland","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.886_bib0027","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.886_bib0028","first-page":"685","article-title":"Neurological complications in oncology and their monitoring and management in clinical practice: a narrative review","volume":"32","author":"Fischer","year":"2024","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1016\/j.jtct.2025.01.886_bib0029","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s11864-022-01035-2","article-title":"Evaluating the patient with neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"23","author":"Fortin Ensign","year":"2022","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.886_bib0030","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1002\/hem3.72","article-title":"Remission after CAR T-cell therapy: do lymphoma patients recover a normal life?","volume":"8","author":"Perthus","year":"2024","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.886_bib0031","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/cncr.34557","article-title":"Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy","volume":"129","author":"Dhawale","year":"2023","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.886_bib0032","first-page":"W32","article-title":"Measuring patient self-reported cognitive function: development of the functional assessment of cancer therapy-cognitive function instrument","volume":"7","author":"Wagner","year":"2009","journal-title":"J Support Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.886_bib0034","doi-asserted-by":"crossref","first-page":"pkz099","DOI":"10.1093\/jncics\/pkz099","article-title":"Identifying cancer-related cognitive impairment using the FACT-cog perceived cognitive impairment","volume":"4","author":"Dyk","year":"2020","journal-title":"JNCI Cancer Spectr"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.886_bib0035","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1470-2045(10)70294-1","article-title":"International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer","volume":"12","author":"Wefel","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2025.01.886_bib0036","series-title":"Hopkins Verbal Learning Test\u2013Revised. Administration Manual","author":"Brandt","year":"2001"},{"key":"10.1016\/j.jtct.2025.01.886_bib0037","series-title":"Multilingual Aphasia Examination","author":"Benton","year":"1994"},{"key":"10.1016\/j.jtct.2025.01.886_bib0038","series-title":"A Compendium of Neuropsychological Tests: Administration, Norms and Commentary","author":"Spreen","year":"1998"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.886_bib0039","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0887-6177(03)00039-8","article-title":"Trail making test A and B: normative data stratified by age and education","volume":"19","author":"Tombaugh","year":"2004","journal-title":"Arch Clin Neuropsychol"},{"issue":"7-8","key":"10.1016\/j.jtct.2025.01.886_bib0040","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1080\/13854046.2020.1769192","article-title":"Validity of teleneuropsychology for older adults in response to COVID-19: a systematic and critical review","volume":"34","author":"Marra","year":"2020","journal-title":"Clin Neuropsychol"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.886_bib0041","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3758\/s13423-012-0296-9","article-title":"Is the Web as good as the lab? Comparable performance from web and lab in cognitive\/perceptual experiments","volume":"19","author":"Germine","year":"2012","journal-title":"Psychon Bull Rev"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.886_bib0042","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/13854046.2018.1535662","article-title":"Digital neuropsychology: challenges and opportunities at the intersection of science and software","volume":"33","author":"Germine","year":"2019","journal-title":"Clin Neuropsychol"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.886_bib0043","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12888-020-02885-6","article-title":"The reliability and validity of PHQ-9 in patients with major depressive disorder in psychiatric hospital","volume":"20","author":"Sun","year":"2020","journal-title":"BMC Psychiatry"},{"issue":"9","key":"10.1016\/j.jtct.2025.01.886_bib0044","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.886_bib0045","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.jtct.2025.01.886_bib0046","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.886_bib0047","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2025.01.886_bib0048","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s41687-018-0071-4","article-title":"Important differences and meaningful changes for the functional assessment of cancer therapy-cognitive function (FACT-Cog)","volume":"2","author":"Bell","year":"2018","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.886_bib0049","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1037\/0022-006X.59.1.12","article-title":"Clinical significance: a statistical approach to defining meaningful change in psychotherapy research","volume":"59","author":"Jacobson","year":"1991","journal-title":"J Consult Clin Psychol"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.886_bib0050","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0277-5379(82)90242-5","article-title":"Serum lactate dehydrogenase (LDH) as a prognostic index for non-Hodgkin's lymphoma","volume":"18","author":"Endrizzi","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.jtct.2025.01.886_bib0051","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.01.886_bib0052","article-title":"Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma","author":"Forero-Forero","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.jtct.2025.01.886_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103126","article-title":"Cognition following chimeric antigen receptor T-cell therapy: a systematic review","volume":"140","author":"Kazzi","year":"2023","journal-title":"J Autoimmun"},{"issue":"23","key":"10.1016\/j.jtct.2025.01.886_bib0054","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1002\/cncr.28323","article-title":"Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant","volume":"119","author":"Jones","year":"2013","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.886_bib0055","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/pon.3159","article-title":"Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study","volume":"22","author":"Scherwath","year":"2013","journal-title":"Psychooncology"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.886_bib0056","doi-asserted-by":"crossref","first-page":"e2021","DOI":"10.1002\/onco.13867","article-title":"Neurocognitive impairment after hematopoietic stem cell transplant for hematologic malignancies: phenotype and mechanisms","volume":"26","author":"Harrison","year":"2021","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.886_bib0057","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11764-018-0692-x","article-title":"Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment","volume":"12","author":"Bray","year":"2018","journal-title":"J Cancer Surviv"},{"issue":"12","key":"10.1016\/j.jtct.2025.01.886_bib0058","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/jnci\/djab027","article-title":"Measuring self-reported cancer-related cognitive impairment: recommendations from the cancer neuroscience initiative working group","volume":"113","author":"Henneghan","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtct.2025.01.886_bib0059","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-clinpsy-050817-084903","article-title":"Cognitive effects of cancer and cancer treatments","volume":"14","author":"Ahles","year":"2018","journal-title":"Annu Rev Clin Psychol"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.886_bib0060","doi-asserted-by":"crossref","first-page":"e1256","DOI":"10.1212\/WNL.0000000000007094","article-title":"Systemic inflammation during midlife and cognitive change over 20 years: the ARIC study","volume":"92","author":"Walker","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.886_bib0061","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000514651","article-title":"Impact of comorbidity burden on cognitive decline: a prospective cohort study of older adults with dementia","volume":"50","author":"Kao","year":"2021","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.886_bib0062","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.ctrv.2012.05.002","article-title":"Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review","volume":"38","author":"Hutchinson","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.886_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101287","article-title":"Toxicities associated with adoptive cellular therapies","volume":"34","author":"Hansen","year":"2021","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725009145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725009145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:52:14Z","timestamp":1775004734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725009145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2666636725009145"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.01.886","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Cognitive Outcomes in Adult Patients Receiving Chimeric Antigen Receptor T-Cell Therapies","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.01.886","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}